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Although many studies have shown that administration of stem cells after focal cerebral ischemia improves brain damage,
very little data are available concerning the damage induced by global cerebral ischemia. The latter causes neuronal death in
selectively vulnerable areas, including the hippocampal CA1 region. We tested the hypothesis that intravenous infusion of bone
marrowderived stromal cells (mesenchimal stem cells, MSC) reduce brain damage after transient global ischemia. In adult male
Sprague-Dawleyratstransientglobalischemiawasinducedusingbilateralcommoncarotidarteryocclusionfor20mininaddition
to controlled hypotension. Five days after, the animals were anaesthetized with urethane and the brain was ﬁxed, sectioned and
stained with hematoxylin-eosin to investigate histological damage. MSC did not fully protect against ischemic damage, as the
number of viable neurons in this group was lower than in normal (sham-operated) rats. However, in MSC-treated rats the number
of viable CA1pyramidal neurons was signiﬁcally higher than in rats that hadbeen subjected toischemia but not treated with MSC.
We conclude that intravenous administration of MSC after transient global ischemia reduces hippocampal damage.
1.Introduction
Bone marrow (BM) contains populations of precursors
that are multipotent and have the characteristics of stem
cells of nonhematopoietic tissues. The precursors of non-
hematopoietictissuesarereferredtoasbonemarrowstromal
cells (BMSCs) or mesenchymal stem cells (MSCs). They
have attracted interest because of their capacity for self-
renewal in a number of nonhematopoietic tissues and
their multipotentiality for diﬀerentiation. They are able
to cross the blood-brain barrier, to migrate throughout
forebrain and cerebellum, and to diﬀerentiate to some
extent into astrocytes and neurons. Despite their transdif-
ferentiation potential, recent data have shown that MSCs
display a signiﬁcant capacity of decreasing inﬂammation,
modulating immune responses, and protecting tissues from
injuries, mostly through bystander paracrine mechanisms
[1]. Cellular therapy of brain injury, including stroke and
anoxic damage, stemmed from the assumption that stem
cells diﬀerentiate and replace dead cells [2]. However, the
usefulness of these cells in rebuilding neural networks is
controversial [3], and several studies have now provided
signiﬁcant evidence that other mechanisms are likely to play
a major role in protection and neural repair. These include
induction of neurogenesis [4] and oligodendrogenesis [5],
production of trophic factors [6], and protection from
apoptosis [7] and from oxidative stress [8] possibly exerting
an anti-inﬂammatory eﬀect on cells of the innate immunity
such as microglia [9]a n dm a c r o p h a g e s[ 10]. Regardless of
the mechanisms of tissue protection, several data exist con-
cerning the eﬀects of stem cells in the experimental therapy
o ff o c a lc e r e b r a li s c h e m i a[ 6, 11–14], but little research has
been done in global cerebral ischemia, although encouraging
data exist for this model, too [15]. In the present study, we
tested the hypothesis that MSCs administered intravenously
reduce histological damage after global cerebral ischemia in2 Neural Plasticity
rats. Our hypothesis in using these cells for the treatment of
global cerebral ischemia was that after crossing the blood-
brain barrier MSCs preferentially reach the damaged areas
in the brain [15, 16] and are able to produce cytokines
and factors that can be used to reduce apoptosis and
p r o m o t et i s s u er e c o v e r y[ 7]. The experimental model we
choose is the “two-vessel occlusion” (2VO). In this model,
reversible high-grade forebrain ischemia is produced by
bilateral common carotid artery occlusions combined with
systemic hypotension [17]. While techniques using selected
arterial occlusion better reproduce the ischemia seen in
human stroke, this model of global cerebral ischemia causes
abraindamagesimilartothatobservedinpatientsfollowing,
for example, cardiorespiratory arrest [18]. To evaluate the
damage induced by global brain ischemia, we counted the
number of surviving hippocampal pyramidal cells. These
cells are selectively vulnerable to global ischemic damage and
can therefore gauge the eﬀects of such a damage [19].
2.MaterialsandMethods
2.1.IsolationandCharacterizationofMesenchymalStemCells.
Murine bone marrow-derived MSCs were isolated from 6-
to 8-week-old C57BL/6J mice (Harlan, S. Pietro al Natisone,
Italy) as described elsewhere [20]. In brief, marrow cells,
ﬂushed out of tibias and femurs, were plated in 75cm2
tissue culture ﬂasks (Sarstedt, Numbrecht, Germany) at the
concentration of 0,3 to 0,4 × 106 cells/cm2 using Murine
Mesencult as medium (Stem Cell Technologies, Vancouver,
British Columbia, Canada). Cells were cultured in plastic
plates as adherent cells and kept in a humidiﬁed 5% CO2
incubator at 37
◦C, refreshing medium every 3 days for
about 6 weeks when cells reached 80% conﬂuence. On
treatment with 0.05% trypsin solution containing 0.02%
EDTA (Sigma-Aldrich, St. louis, MO), marrow cells were
plated in 25cm2 ﬂasks at 1.2 to 2.0 × 104 cells/cm2 for the
subsequent 4 or 5 passages. Thereafter, cells were routinely
seeded at 4 to 10 × 103 cells/cm2. Mature MSCs, obtained
after four to ﬁve passages in culture, were deﬁned by the
expression on their surface of CD9, Sca-1, CD73, and CD44
antibodies and by the lack of the hematopoietic markers
CD45, CD34, and CD11b.
Human bone marrow samples were obtained from
healthy donors undergoing bone marrow explant for allo-
geneic transplantation procedures as described elsewhere
[21]. Brieﬂy, bone marrow mononuclear cells were isolated
by density gradient centrifugation (1,077g/ml; Lympholyte
Cell Separation Media, Cedar Lane, Hornby, ON, Canada)
and seeded at the density of 25–30 × 106 cells per 75cm2
tissue culture ﬂasks in Human Mesencult as medium (Stem
C e l lT e c h n o l o g i e s ,V a n c o u v e r ,B r i t i s hC o l u m b i a ,C a n a d a )
and incubated at 37
◦C and 5% CO2. At 80% conﬂuence,
cells were harvested with 0.05% trypsin and 0.02% EDTA
a n dp l a t e di n7 5 c m 2 ﬂasks at the density of 7 × 105
cells. Characterization of MSCs in culture was achieved by
ﬂow cytometry. Typical CD34−, CD45−, CD14−, CD73+,
CD44+, and CD105+ cells were usually obtained after three
passages in culture.
2.2. Induction of Global Forebrain Ischemia. Adult male
Sprague-Dawleyratsweighing270–300gwereobtainedfrom
Harlan Italy San Pietro al Natisone, Udine, Italy. The animals
were fasted during the night preceding the operation with
free access to water. Anesthesia was induced with isoﬂurane
(5% induction, 1-2% maintenance) in a mixture of N2O
and O2 (50:50) by a face mask. The surgical operations
were made on a heated pad. Transient global ischemia
was induced by bilateral occlusions of the common carotid
arteries for 20 minutes. Ischemia duration was calculated as
previously reported [22], leading to a reproducible neuronal
damage in the CA1 region of the hippocampus, cortical
layers 3, 5, and 6 and the basal ganglia. Brieﬂy, both
femoral arteries and right femoral vein were exposed and
catheterized with Teﬂon catheters. The left femoral artery
wasconnectedtoapressuretransducer(SpectramedStatham
P23XL, Viggo-Spectramed, Oxnard, CA, USA) providing a
recording of arterial pressure through a Grass preampliﬁer,
model 7P14A (Grass Instruments, Quincy, MA, USA), for
continuous recording of arterial pressure. The reversible
forebrain ischemia was induced by combination of bilateral
carotid artery clamping and reduction of mean arterial
blood pressure. The carotid arteries were occluded with
stainless microvascular clamps when blood pressure had
reached 30mmHg and then maintained at 30 ± 1mmHg by
blood withdrawal or reinfusion by the cannula in the right
femoral artery. Ischemia was terminated after 20 minutes
by removal of carotid clamps and by reinfusion of plasma
volume expander (untreated ischemic, N = 4) or of 1mL of
either human or murine MSC bolus (3 · 106MSC/ml saline)
(treated ischemic, N = 3) by the cannula in the left femoral
vein. 3 rats represented the sham-operated group; they were
subjected to the surgical procedures except the ischemia and
the pressure control. After the procedure, each rat recovered
in a heated chamber for 2 hours then was returned to a light-
and temperature-controlled facility.
2.3. Histology. Five days after ischemia, animals were anaes-
thetized with urethane (150mg/100g bw ip) and transcar-
dially perfused with saline followed by ﬁxation with ice-
cold 4% paraformaldehyde in phosphate buﬀer. The brains
were postﬁxed in ice-cold 4% paraformaldehyde for one
hour then cryoprotected in 30% sucrose. Coronal cryostat
sections (8μm) were mounted onto poly-L-lysine-coated
slides. Sections were stained with hematoxylin eosin.
2.4. Quantiﬁcation of the Ischemic Damage. Hematoxylin-
eosin-stained sections were used to assess the extent of
ischemicdamage.20coronalsectionsweretakenbetween3.8
and 3.96mm posterior to the bregma. The neuronal count
was made under a light microscope at 20x magniﬁcation in
12 randomly selected hippocampal sections of 1,7 · 104μm2
in the CA1 region. The number of neurons exhibiting
ischemic cell change and morphologically normal neurons
was counted in each selected hippocampal section. Ischemic
neurons were deﬁned by an intense, darkly stained pyknotic
nucleus, surrounded by eosinophilic cytoplasm. Statistical
analysis was carried out with analysis of variance (ANOVA)Neural Plasticity 3
(a) (b) (c)
Figure 1: Microphotographs (20x) of pyramidal neurons in the CA1 region of the hippocampus. Sections from (a) sham-operated rat,
(b) ischemic untreated, and (c) ischemic MSC-treated rat. Shrunken neurons are indicated by arrows. Images were obtained 5 days after
ischemia.
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Figure 2: Number of vital neurons after ischemia in the various
groups. Bars show mean and standard deviation. Probability values
are for one-way analysis of variance (ANOVA) and for post hoc
Bonferroni’s Multiple Comparison Test.
followed by Bonferroni’s Multiple Comparison Test. All
computations were done using the program GraphPad
Prism,version4.03forWindows,byGraphPadSoftware,San
Diego California (USA).
3. Results
Data were obtained from 10 rats, treated as follows: 3 sham-
operated, 4 ischemic untreated, 2 ischemic treated with
human MSCs, and 1 ischemic treated with mouse MSCs.
Results are summarized in Table 1. Since all MSC-treated
rats showed superimposable results (see Table 1), their data
were pooled for further statistical analysis. Figure 1 shows
representative examples of microphotographs of pyramidal
Table 1: Number of cells/ﬁeld in the various experiments. Same
data as Figure 2, however, note that in Figure 2 the 2 MSC groups
(human and mouse) were pooled. See text for more information.
Sham operated Ischemia,
untreated
Ischemia,
human MSCs
Ischemia,
mouse MSCs
72 28 59 59
71 27 51
73 27
44
neurons of CA1 hippocampal region of sham-operated (a),
ischemic-untreated (b), and ischemic MSC-treated rats (c).
Average neuronal count (cells/ﬁeld) in the CA1 hippocampal
region was (mean ± SD) 72.05±0.88 for sham-operated rats
(N = 3), 32 ± 9 for untreated ischemic rats (N = 4), and
56 ± 5 for MSC-treated ischemic rats (N = 3). Figure 2
graphically reports these values and the corresponding
statistical analysis. Analysis of variance shows a statistically
signiﬁcant diﬀerence, and post hoc tests show that all 3
groupsarestatisticallydiﬀerentfromeachother.Asexpected,
ischemic-untreated rats were worse than sham-operated
ones (P<. 001). Ischemic MSC-treated rats were better than
ischemic untreated, having a signiﬁcantly higher number
of surviving cells (P<. 01). However, count of surviving
neurons in ischemic MSC-treated rats was lower than in
sham-operated rats (P<. 05), thus showing that MSC
treatment did not cause a total protection of the ischemic
neurons.
4. Discussion
The present study investigated the therapeutic potential of
MSCs in a rat model of diﬀuse neuronal damage induced
by global ischemia. Our results suggest that intravenously
i n j e c t e dM S C sh a v eap o s i t i v ee ﬀect on neuronal survival
in this type of neuronal damage. In fact, we showed that
the number of surviving neurons in the CA1 region of the
hippocampus of ischemic, MSC-treated rats is signiﬁcantly
higher than that of ischemic, untreated ones. As a word of
caution, MSC-treated rats were still worse than fully normal4 Neural Plasticity
(sham-operated) animals, thus showing that this therapy,
albeit eﬀective, does not cause a full protection of the tissue.
As for the mechanisms that improve ischemic damage upon
MSCsinjectionafterglobalischemia,ourdatadonotdirectly
address the mechanisms responsible for the therapeutic
eﬀects of intravenous administration of bone marrow cells
on cerebral infarction. One possibility may be that the MSC
integrate into the tissue and replace damaged cells; however,
the short time elapsed from ischemia to assessment (5 days)
makes it, in our opinion, very unlikely. Despite the fact
that a longer observation could have allowed to detect any
further improvement due to the possible long-term capacity
of providing tissue repair in the ischemic brain, the lack of
evidence of engraftment in this study and, more important,
the large body of evidence arising from the current literature
[1, 3] suggest that, MSC transdiﬀerentiation into neural
cells does not play a major role in brain tissue repair. Since
the reconstruction of neural circuitry is not always essential
for functional recovery [23], a more reasonable hypothe-
sis is that MSC therapeutic eﬀect is based on bystander
mechanisms leading to tissue protection and repair. In
particular, MSC intravenous administration has been shown
to lead to production of trophic factors [6, 24], which may
be the functional consequence of inﬂammatory, hypoxic,
and oxidative stress-associated insults [25]. Moreover, MSC
in vivo administration results also in the downregulation
of several stress-associated molecules involved in oxidative
stress detoxiﬁcation [26]. Finally, MSCs rescue also ischemic
neurons from apoptosis [7]. All these features are supported
by the global gene expression proﬁle of therapeutic MSCs,
which is enriched by anti-inﬂammatory, antiapoptotic, and
trophicgenes[27].Theresultsprovidedinthisstudyconﬁrm
that MSCs are endowed with a remarkable therapeutic
plasticity potentially useful for a vast range of diseases
sustained by multiple pathogenic mechanisms. Due to their
known safety in humans, further studies could expand
pioneer experience with MSCs in stroke [28].
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